Novigenix is an innovative Swiss molecular diagnostics company specializing in new generation blood tests for early detection of cancer. Colox®, our lead product is a proven molecular blood test designed to significantly reduce mortality from colorectal cancer through early detection and follow-up colonoscopy. Novigenix’s technology is based on a new generation of predictive gene expression profiles of circulating blood cells and concentration profile of tumor-derived protein markers in combination with state-of-the-art mathematical analytical models. Our predictive molecular signatures of biomarkers provide new and accurate solutions for the early detection of cancer. Generating insights from tumor-host interaction in order to detect cancer as early as possible and tailor the right treatment for the right patient. We are pioneering the field of immuno-transcriptomics with passion for improving health outcomes.
Total Funding: €1 M
Funding Stage: Funded
Business Stage: Scaling Up
Market: B2B
Company Size: 1 to 25
Founded: 2014
